Is It Too Late To Consider ImmunityBio (IBRX) After This Year’s Share Price Surge?
- This article examines whether ImmunityBio at US$7.65 still offers value or if most of the opportunity is already reflected in the price, by breaking down what the current market level may be implying.
- The stock has had a mixed run, with a 3.2% return over the last 7 days, a 21.8% decline over 30 days, a 278.7% return year to date and 158.4% over the past year, while the 5 year return sits at a 59.3% decline and the 3 year return is 355.4%.
- Recent coverage has focused on ImmunityBio’s position in the biotech space and investor interest around its pipeline and funding, all of which help shape sentiment around the shares. These developments provide important context for the recent sharp swings in the stock price.
- ImmunityBio currently has…
Source link
